ISIS-GSK4Rx

**ISIS-GSK4Rx** is an antisense oligonucleotide drug developed by Isis Pharmaceuticals (now Ionis Pharmaceuticals) in collaboration with GlaxoSmithKline (GSK) for an undisclosed ocular disease. As a Generation 2+ antisense drug, it binds to specific messenger RNA to inhibit the production of a disease-causing protein, offering a targeted approach to treat severe eye conditions where traditional therapies may fall short. In 2013, it was designated as a development candidate, earning Isis a $5 million milestone payment from GSK, with Isis responsible for advancing it to Phase 2 proof-of-concept, after which GSK holds an option to exclusively license it. Isis was also eligible for additional milestones and double-digit royalties on potential sales.[1][2][12]